



DR. ANNE MARINIER

Director of Medicinal Chemistry

Institut de recherche en immunologie et en oncologie (IRIC)

Université de Montréal

BIOGRAPHY: Dr. Anne Marinier brings along more than 25 years of experience in medicinal chemistry and a strong industry expertise in all aspects of drug discovery. Before joining IRIC, Dr Marinier was Group Leader in the Drug Discovery Research group at Bristol-Myers Squibb (BMS) and was involved in the identification of pre-clinical candidates while contributing to the progression of programs in oncology, immunology and infectious diseases. As director of IRIC Medicinal Chemistry, she currently heads IRIC's medicinal chemistry platform, which comprises more than 40 chemists and biologists and supports drug discovery programs from IRIC scientists and collaborators. The laboratory has a strong expertise in Structure-Activity Relationships development and compound optimization and

focuses also on structure-based drug design as well as devising chemical probes for novel biological target identification. Two molecules discovered in collaboration with BMS, have successfully completed Phase I trial and one of them will be further progressed in Phase II. A further compound, UM171, an enhancer of hematopoietic stem cell renewal, was developed with Dr Guy Sauvageau, and has just completed a Phase I/II clinical study. This has led to the creation of the biotechnology company ExCellThera, for which she is one of the founders and Chief Technology Officer, Chemistry.

PRESENTATION TITLE: *Chemo-genomic screening in AML: a new approach to identify therapeutic strategies in cancer*